MENU

INO Stock Inovio Pharmaceuticals (INO, $2.28) RSI Indicator left the oversold zone on January 07, 2025

A.I.dvisor
at Tickeron.com
Loading...
INO - Inovio Pharmaceuticals
RSI signal
Bullish Trend
Odds of UP Trend
Tickeron
RSI signal
Price: $2.28
Daily change: +$0.35 (+18.13%)
Daily volume: 4.6M
Capitalization: $82.3M
Industry: Biotechnology
This is a signal that INO's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options. A.I.dvisor looked back and found 51 similar cases where INO's RSI Indicator left the oversold zone, and in of them led to a successful outcome. Odds of Success:

INO's RSI Oscillator climbs out of oversold territory

The RSI Indicator for INO moved out of oversold territory on January 07, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 51 similar instances when the indicator left oversold territory. In of the 51 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on INO as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for INO just turned positive on January 02, 2025. Looking at past instances where INO's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in of 242 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

INO broke above its upper Bollinger Band on January 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INO entered a downward trend on December 23, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.021) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). INO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (256.410) is also within normal values, averaging (263.573).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of synthetic vaccines and immune therapies for cancers and infectious diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
660 West Germantown Pike
Phone
+1 267 440-4200
Employees
122
Web
https://www.inovio.com